Research
Energy balance
GLP-1 agonists have drawbacks in treating obesity.
Practitioners should be aware of the limitations of GLP-1 agonists in obesity treatment.
LimitedRefutesmedium confidence
This Viewpoint discusses the drawbacks of using glucagon-like peptide 1 (GLP-1) agonists to treat obesity.
Why this rating
The abstract presents an expert opinion.
Source
GLP-1 Agonists for Obesity—A New Recipe for Success?
Dariush Mozaffarian · JAMA · 2024
DOI 10.1001/jama.2024.2252
otherCited 72×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →